Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/201342
Title: | Docosahexaenoic Acid and Melatonin Prevent Impaired Oligodendrogenesis Induced by Intrauterine Growth Restriction (IUGR) |
Author: | Kühne, Britta Anna Vázquez Aristizabal, Paula Fuentes Amell, Mercè Pla, Laura Loreiro, Carla Gómez Catalán, Jesús Gratacós Solsona, Eduard Illa Armengol, Míriam Barenys Espadaler, Marta |
Keywords: | Creixement fetal Malalties del sistema nerviós Cultiu cel·lular Diferenciació cel·lular Melatonina Fetal growth Nervous system Diseases Cell culture Cell diferentiation Melatonin |
Issue Date: | 23-May-2022 |
Publisher: | MDPI |
Abstract: | In this study, our aims were to characterize oligodendrogenesis alterations in fetuses with intrauterine growth restriction (IUGR) and to find therapeutic strategies to prevent/treat them using a novel rabbit in vitro neurosphere culture. IUGR was surgically induced in one uterine horn of pregnant rabbits, while the contralateral horn served as a control. Neural progenitor cells (NPCs) were obtained from pup's whole brain and cultured as neurospheres mimicking the basic processes of brain development including migration and cell differentiation. Five substances, chosen based on evidence provided in the literature, were screened in vitro in neurospheres from untreated rabbits: Docosahexaenoic acid (DHA), melatonin (MEL), zinc, 3,3',5-Triiodo-L-thyronine (T3), and lactoferrin (LF) or its metabolite sialic acid (SA). DHA, MEL and LF were further selected for in vivo administration and subsequent evaluation in the Neurosphere Assay. In the IUGR culture, we observed a significantly reduced percentage of oligodendrocytes (OLs) which correlated with clinical findings indicating white matter injury in IUGR infants. We identified DHA and MEL as the most effective therapies. In all cases, our in vitro rabbit neurosphere assay predicted the outcome of the in vivo administration of the therapies and confirmed the reliability of the model, making it a powerful and consistent tool to select new neuroprotective therapies. |
Note: | Reproducció del document publicat a: https://doi.org/10.3390/biomedicines10051205 |
It is part of: | Biomedicines, 2022, vol. 10, num. 5, p. 1205 |
URI: | http://hdl.handle.net/2445/201342 |
Related resource: | https://doi.org/10.3390/biomedicines10051205 |
ISSN: | 2227-9059 |
Appears in Collections: | Articles publicats en revistes (Cirurgia i Especialitats Medicoquirúrgiques) Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) Articles publicats en revistes (BCNatal Fetal Medicine Research Center) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
726768.pdf | 3.24 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License